A secretagogue-small interfering RNA conjugate confers resistance to cytotoxicity in a cell model of Sjögren's syndrome

Arthritis and Rheumatism

Volumn 63, Issue 10, 2011, Pages 3116-3125

  Pauley, Kaleb M ^a   Gauna, Adrienne E ^a   Grichtchenko, Irina I ^b   Chan, Edward K L ^a   Cha, Seunghee ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF DENTISTRY   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; CARBACHOL; CARBACHOL SMALL INTERFERING RNA CONJUGATE; CASPASE 3; CHOLINE; GROWTH HORMONE SECRETAGOGUE; LIPOFECTAMINE; MUSCARINIC M3 RECEPTOR; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; CONJUGATE; CONTROLLED STUDY; CYTOTOXICITY; ENDOCYTOSIS; EPITHELIUM CELL; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE TARGETING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SALIVARY GLAND; SJOEGREN SYNDROME;

CARBACHOL; CASPASE INHIBITORS; CELL LINE; CHOLINERGIC AGONISTS; HUMANS; RNA INTERFERENCE; RNA, SMALL INTERFERING; SALIVARY GLANDS; SJOGREN'S SYNDROME;

EID: 80053553412     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.30450     Document Type: Article

References (29)

1. Bulosan M, Pauley KM, Yo K, Chan EK, Katz J, Peck AB, et al. Inflammatory caspases are critical for enhanced cell death in the target tissue of Sjögren's syndrome before disease onset. Immunol Cell Biol 2008; 87: 81-90.
2. Cha S, Brayer J, Gao J, Brown V, Killedar S, Yasunari U, et al. A dual role for interferon-γ in the pathogenesis of Sjögren's syndrome-like autoimmune exocrinopathy in the nonobese diabetic mouse. Scand J Immunol 2004; 60: 552-65. (Pubitemid 39665100)
3. Cha S, van Blockland SC, Versnel MA, Homo-Delarche F, Nagashima H, Brayer J, et al. Abnormal organogenesis in salivary gland development may initiate adult onset of autoimmune exocrinopathy. Exp Clin Immunogenet 2001; 18: 143-60. (Pubitemid 32830559)
4. Robinson CP, Yamamoto H, Peck AB, Humphreys-Beher MG,. Genetically programmed development of salivary gland abnormalities in the NOD (nonobese diabetic)-scid mouse in the absence of detectable lymphocytic infiltration: a potential trigger for sialoadenitis of NOD mice. Clin Immunol Immunopathol 1996; 79: 50-9. (Pubitemid 26150330)
5. Cha S, Nagashima H, Brown VB, Peck AB, Humphreys-Beher MG,. Two NOD Idd-associated intervals contribute synergistically to the development of autoimmune exocrinopathy (Sjögren's syndrome) on a healthy murine background. Arthritis Rheum 2002; 46: 1390-8. (Pubitemid 34525849)
6. Rana TM,. Illuminating the silence: understanding the structure and function of small RNAs. Nat Rev Mol Cell Biol 2007; 8: 23-36. (Pubitemid 46012012)
7. Lopez-Fraga M, Martinez T, Jimenez A,. RNA interference technologies and therapeutics: from basic research to products. BioDrugs 2009; 23: 305-32.
8. Wu SY, McMillan NA,. Lipidic systems for in vivo siRNA delivery. AAPS J 2009; 11: 639-52.
9. Hart SL,. Multifunctional nanocomplexes for gene transfer and gene therapy. Cell Biol Toxicol 2010; 26: 69-81.
10. Mykhaylyk O, Zelphati O, Rosenecker J, Plank C,. siRNA delivery by magnetofection. Curr Opin Mol Ther 2008; 10: 493-505.
11. Yu B, Zhao X, Lee LJ, Lee RJ,. Targeted delivery systems for oligonucleotide therapeutics. AAPS J 2009; 11: 195-203.
12. Endoh T, Ohtsuki T,. Cellular siRNA delivery using cell-penetrating peptides modified for endosomal escape. Adv Drug Deliv Rev 2009; 61: 704-9.
13. Kim SS, Garg H, Joshi A, Manjunath N,. Strategies for targeted nonviral delivery of siRNAs in vivo. Trends Mol Med 2009; 15: 491-500.
14. Livak KJ, Schmittgen TD,. Analysis of relative gene expression data using real-time quantitative PCR and the 2 -ΔΔC T method. Methods 2001; 25: 402-8. (Pubitemid 34164012)
15. Regehr WG, Atluri PP,. Calcium transients in cerebellar granule cell presynaptic terminals. Biophys J 1995; 68: 2156-70.
16. Cryns VL, Bergeron L, Zhu H, Li H, Yuan J,. Specific cleavage of α-fodrin during Fas- and tumor necrosis factor-induced apoptosis is mediated by an interleukin-1β-converting enzyme/Ced-3 protease distinct from the poly(ADP-ribose) polymerase protease. J Biol Chem 1996; 271: 31277-82. (Pubitemid 26408575)
17. Janicke RU, Ng P, Sprengart ML, Porter AG,. Caspase-3 is required for α-fodrin cleavage but dispensable for cleavage of other death substrates in apoptosis. J Biol Chem 1998; 273: 15540-5. (Pubitemid 28298165)
18. Tobin G, Giglio D, Lundgren O,. Muscarinic receptor subtypes in the alimentary tract. J Physiol Pharmacol 2009; 60: 3-21.
19. Perry C, Baker OJ, Reyland ME, Grichtchenko II,. PKCαβγ- and PKCδ-dependent endocytosis of NBCe1-A and NBCe1-B in salivary parotid acinar cells. Am J Physiol Cell Physiol 2009; 297: C1409-23.
20. Brayer JB, Cha S, Nagashima H, Yasunari U, Lindberg A, Diggs S, et al. IL-4-dependent effector phase in autoimmune exocrinopathy as defined by the NOD.IL-4-gene knockout mouse model of Sjögren's syndrome. Scand J Immunol 2001; 54: 133-40. (Pubitemid 32592338)
21. Cha S, Nagashima H, Brown VB, Peck AB, Humphreys-Beher MG,. Two NOD Idd-associated intervals contribute synergistically to the development of autoimmune exocrinopathy (Sjögren's syndrome) on a healthy murine background. Arthritis Rheum 2002; 46: 1390-8. (Pubitemid 34525849)
22. Cha S, Singson E, Cornelius J, Yagna JP, Knot HJ, Peck AB,. Muscarinic acetylcholine type-3 receptor desensitization due to chronic exposure to Sjögren's syndrome-associated autoantibodies. J Rheumatol 2006; 33: 296-306. (Pubitemid 43209306)
23. Gao J, Cha S, Jonsson R, Opalko J, Peck AB,. Detection of anti-type 3 muscarinic acetylcholine receptor autoantibodies in the sera of Sjögren's syndrome patients by use of a transfected cell line assay. Arthritis Rheum 2004; 50: 2615-21. (Pubitemid 39062723)
24. Gao J, Killedar S, Cornelius JG, Nguyen C, Cha S, Peck AB,. Sjögren's syndrome in the NOD mouse model is an interleukin-4 time-dependent, antibody isotype-specific autoimmune disease. J Autoimmun 2006; 26: 90-103. (Pubitemid 43138879)
25. Nguyen C, Cornelius J, Singson E, Killedar S, Cha S, Peck AB,. Role of complement and B lymphocytes in Sjögren's syndrome-like autoimmune exocrinopathy of NOD.B10-H2b mice. Mol Immunol 2006; 43: 1332-9. (Pubitemid 43356373)
26. Nguyen KH, Brayer J, Cha S, Diggs S, Yasunari U, Hilal G, et al. Evidence for antimuscarinic acetylcholine receptor antibody-mediated secretory dysfunction in NOD mice. Arthritis Rheum 2000; 43: 2297-306.
27. Robinson CP, Bounous DI, Alford CE, Peck AB, Humphreys-Beher MG,. Aberrant expression and potential function for parotid secretory protein (PSP) in the NOD (non-obese diabetic) mouse. Adv Exp Med Biol 1998; 438: 925-30. (Pubitemid 28303841)
28. Robinson CP, Yamachika S, Alford CE, Cooper C, Pichardo EL, Shah N, et al. Elevated levels of cysteine protease activity in saliva and salivary glands of the nonobese diabetic (NOD) mouse model for Sjögren syndrome. Proc Natl Acad Sci U S A 1997; 94: 5767-71.
29. Robinson CP, Yamamoto H, Peck AB, Humphreys-Beher MG,. Genetically programmed development of salivary gland abnormalities in the NOD (nonobese diabetic)-scid mouse in the absence of detectable lymphocytic infiltration: a potential trigger for sialoadenitis of NOD mice. Clin Immunol Immunopathol 1996; 79: 50-9. (Pubitemid 26150330)